logo
Share SHARE
FONT-SIZE Plus   Neg

Strides Arcolab Gets US FDA Nod For Vancomycin Oral Capsules

Strides Arcolab Ltd. said it had received approval from the US FDA to market its generic Vancomycin Hydrochloride capsules in the strength of 125mg and 250 mg.

Vancomycin capsules is glycopeptides antibiotic used in the prophylaxis and treatment of infections caused by Gram-positive bacteria. It has traditionally been reserved as a drug of last resort, used only after treatment with other antibiotics had failed.

The company plans to launch the product immediately through US-based Alvogen on a profit-sharing basis, the company said.

As per IMS health data, Vancomycin capsules had total US sales of $332 million for the twelve months ended February 12, with no prior generic approvals.

Commenting on the development, Strides Group CEO Arun Kumar said, "Oral Vancomycin development is one among the many value generics programmes being undertaken at the Strides Group with a special focus to develop niche and difficult-to-manufacture products.''

At the BSE, Strides Arcolab closed Wednesday's trading at Rs 631.90, after touching a 52-week high of Rs.649 in the early trading session.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

More Breaking News

0 Articles
Editors Pick
Kik Interactive Inc., the parent of chat app Kik, said it will launch a new cryptocurrency or token called Kin for use in everyday digital services, such as chat, social media and payments. Kik said it has decided to propose a new ecosystem of digital services that will be truly open and decentralized, and will start with a new cryptocurrency. Several companies have pulled advertisements from Sean Hannity's Fox News show after he continued to promote a conspiracy theory about Democratic National Committee staffer Seth Rich's death. Hannity has come under fire for spreading a conspiracy theory linking Rich's killing to Wikileaks. Best Buy Co., Inc. reported lower profit in its first quarter on the absence of last year's CRT settlement proceeds. However, earnings per share topped market estimates significantly with higher comparable sales. Looking ahead, for the second quarter, the company projects higher comparable sales, and also lifted fiscal 2018 forecast for higher growth.In pre-market, shares were gaining 11.9 percent
comments powered by Disqus
Follow RTT